Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 57 Neoplasm Metastasis 21 Carcinoma, Non-Small-Cell Lung 9 Stomach Neoplasms 8 Brain Neoplasms 8 Colorectal Neoplasms 7 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Endometrial Neoplasms 4 Salivary Gland Neoplasms 3 Recurrence 3 Neoplasms 3 Esophageal Neoplasms 3 Adenocarcinoma 3 Prostatic Neoplasms 2 Meningeal Carcinomatosis 2 HER2-positive Gastric Cancer 2 Colonic Neoplasms 2 Breast Cancer With Brain Metastasis 2 Advanced Solid Tumor 2 Advanced Breast Cancer 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Unresectable Locally Recurrent Breast Cancer 1

Interventions

Trastuzumab 14 pertuzumab 10 Docetaxel 7 tucatinib 4 pyrotinib 4 Paclitaxel 4 Capecitabine 4 Carboplatin 2 Ado-Trastuzumab Emtansine 2 trastuzumab deruxtecan 1 pegfilgrastim 1 neratinib 1 exemestane 1 dalpiciclib 1 atezolizumab 1 Neoadjuvant Therapy 1 Leuprolide 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Genetic Testing 1 Fulvestrant 1 Fluorodeoxyglucose F18 1 Blood Specimen Collection 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × trastuzumab deruxtecan × 1 year × Clear all

NCT05982678 2025-11-26

ANISE

The Netherlands Cancer Institute

Phase 2 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡